ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
If you purchased or acquired securities in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...
Intellia Therapeutics price target lowered to $50 from $90 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.
What is William Blair’s Estimate for NTLA FY2029 Earnings?
Equities researchers at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Intellia ...
Leerink Partnrs Weighs in on NTLA Q1 Earnings
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Intellia Therapeutics in a research report issued to clients and investors on Thursday, February 27th. Leerink ...
Le Lézard6h
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Novo Nordisk A/S(NVO) Shareholders
Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") of a class action securities lawsuit.
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...